Literature DB >> 32697854

Interferon: The invisible link in the physiopathology of COVID-19 and BCGitis?

Stefano Di Bella1, Paolo Cabas2, Roberta Maria Antonello3, Michele Rizzo2.   

Abstract

Entities:  

Keywords:  BCGitis; COVID-19; Interferon

Mesh:

Substances:

Year:  2020        PMID: 32697854      PMCID: PMC7404370          DOI: 10.1111/sji.12939

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.889


× No keyword cloud information.
Dear editor, Facing the COVID‐19 pandemic, we were intrigued by the difference of incidence and disease severity between men and women (60%‐70% of deaths occurring in men). This disparity remains significant even after age stratification in all age groups (postmenopausal women vs age‐matched men), suggesting a partially hormone‐independent mechanism. Coincidentally, during the last month we were reviewing the infectious complications of Bacillus Calmette‐Guerin (BCG) bladder instillation. BCG is used for non–muscle‐invasive bladder cancer (NMIBC) after standard surgical treatment: surprisingly, among 243 BCGitis cases reported in the literature, only three were female. The higher number of BCGitis in men has been justified so far considering the worldwide M/F ratio for bladder cancer (3.5:1). In addition, for anatomical reasons, traumatic catheterization is more common in men, potentially providing a wider port of entry for systemic BCG dissemination. However, these two issues are not strong enough to justify the overwhelming unbalanced gender ratio found in BCGitis (M/F 49:1). Bacillus Calmette‐Guerin acts against NMIBC mainly by stimulating non‐specific immune response and a torrent of Th‐1 cytokines, including IFN‐γ. IFN‐γ plays a role against intracellular infection by pathogens such as Mycobacterium tuberculosis and Mycobacterium bovis. A reduced level of IFN‐γ has been observed in men, both prior than after surgery. Bacillus Calmette‐Guerin used as a tubercular vaccine is generally administered to young patients and induced IgG and IFNγ generally diminish with age if a booster dose is not given. On the contrary, BCG used as immune therapy for non–muscle‐invasive bladder cancer is administered to adult elderly patients, and according to the schedule of the treatment, the instillations are repeated periodically resulting in a more sustained immune response. Constitutional differences in male and female immune systems have long been described. The underlying biological mechanisms are not fully understood. They are supposed to result from steroid hormones secreted by gonads and/or different cytokines response. With regard to steroid hormones, in vivo studies , , reported a protective role of oestrogens against respiratory infections. For instance, high levels of 17β‐estradiol are related to better clinical outcomes in mice infected with influenza A. Inflammatory immune responses, as well as the number and activity of innate immune cells, are higher in women. Human studies demonstrated that plasmacytoid dendritic cells of woman exhibit increased expression of interferon (IFN)‐α, following toll‐like receptor (TLR)‐7 stimulation. Furthermore, TLR‐associated genes that activate IFN pathway are significantly upregulated in woman after vaccinations. To be kept in mind, both in vitro and in vivo studies demonstrated the efficient role of IFNs against SARS‐CoV. , In light of the above, we hypothesize that major susceptibility of male gender to COVID‐19 and to BCG infection might share a common interferon‐centred physiopathological basis that needs to be deeply investigated (Figure 1).
Figure 1

Schematic diagram of the hypothesized common mechanism for gender disparity in BCGitis and COVID‐19

Schematic diagram of the hypothesized common mechanism for gender disparity in BCGitis and COVID‐19
  12 in total

1.  Modulation of 17beta-estradiol on the number and cytotoxicity of NK cells in vivo related to MCM and activating receptors.

Authors:  Sha Hao; Junli Zhao; Jianjun Zhou; Shuli Zhao; Yali Hu; Yayi Hou
Journal:  Int Immunopharmacol       Date:  2007-10-12       Impact factor: 4.932

2.  Sex differences in cytokine production and surface antigen expression of peripheral blood mononuclear cells after surgery.

Authors:  Satoshi Ono; Hironori Tsujimoto; Shu-Ichi Hiraki; Risa Takahata; Manabu Kinoshita; Hidetaka Mochizuki
Journal:  Am J Surg       Date:  2005-09       Impact factor: 2.565

3.  17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells.

Authors:  Asa K Bengtsson; Elizabeth J Ryan; Daniela Giordano; Dario M Magaletti; Edward A Clark
Journal:  Blood       Date:  2004-05-13       Impact factor: 22.113

4.  Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study.

Authors:  Mona R Loutfy; Lawrence M Blatt; Katharine A Siminovitch; Sarah Ward; Bryan Wolff; Hyoung Lho; Dieu H Pham; Hassan Deif; Elizabeth A LaMere; Margaret Chang; Kevin C Kain; Gabriella A Farcas; Patti Ferguson; Mary Latchford; Gary Levy; James W Dennis; Enoch K Y Lai; Eleanor N Fish
Journal:  JAMA       Date:  2003-12-24       Impact factor: 56.272

5.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 6.  The Xs and Y of immune responses to viral vaccines.

Authors:  Sabra L Klein; Anne Jedlicka; Andrew Pekosz
Journal:  Lancet Infect Dis       Date:  2010-05       Impact factor: 71.421

Review 7.  Human Immunodeficiency Virus 1 and Type I Interferons-Where Sex Makes a Difference.

Authors:  Susanne Maria Ziegler; Marcus Altfeld
Journal:  Front Immunol       Date:  2017-09-28       Impact factor: 7.561

Review 8.  The use of intravesical BCG in urothelial carcinoma of the bladder.

Authors:  Omar Alhunaidi; Alexandre R Zlotta
Journal:  Ecancermedicalscience       Date:  2019-02-26

Review 9.  Managing the adverse events of intravesical bacillus Calmette-Guérin therapy.

Authors:  Karel Decaestecker; Willem Oosterlinck
Journal:  Res Rep Urol       Date:  2015-10-23

10.  Treatment of SARS with human interferons.

Authors:  J Cinatl; B Morgenstern; G Bauer; P Chandra; H Rabenau; H W Doerr
Journal:  Lancet       Date:  2003-07-26       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.